Long-term renal preservation in essential hypertension. Angiotensin converting enzyme inhibition is superior to β-blockade

American Journal of Hypertension

Volumn 9, Issue 9, 1996, Pages 850-853

  Himmelmann, Anders ^a   Hansson, Lennart ^b   Hansson, Bengt Göran ^c   Hedstrand, Hans ^d   Skogström, Kay ^e   Öhrvik, John ^f   Furängen, Andreas ^g  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c HALMSTAD HOSPITAL   (Sweden)

^d CENTRAL HOSPITAL   (Sweden)

^e BORÅS HOSPITAL   (Sweden)

^f SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

adrenoceptor blocker; Angiotensin converting enzyme inhibitor; Atenolol; Cilazapril; Drug treatment; Glomerular filtration rate; Hypertension; Renal function

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHROMIUM 51; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETIC ACID;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY PRESERVATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CILAZAPRIL; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0030250530     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00176-8     Document Type: Article

References (13)

1. 1. Schmieder RE: Nephroprotection by antihypertensive agents. J Cardiovasc Pharmacol 1994;24(suppl 2):S55-S64.
2. 2. Ruilope LM, Alcazar JM, Rodicio JM: Renal consequences of arterial hypertension. J Hypertens 1992; 10(suppl 7):S85-S90.
3. 3. Whelton PK, Perneger TV, Brancati FL, Klag MJ: Epidemiology and prevention of blood pressure-related renal disease. J Hyperterns 1992;10(suppl 7):S77-S84.
4. 4. Luke RG: Can we prevent end-stage renal disease due to hypertension or to diabetes mellitus. JAMA 1992; 268:3119-3120.
5. 5. Himmelmann A, Hansson L, Hansson B-G, et al: ACE inhibition preserves renal function better than β-blockade in the treatment of essential hypertension. Blood Pressure 1995;4:85-90.
6. 6. Hollenberg NK, Swartz SL, Passan DR, Williams GH: Increased glomerular filtration rate after converting enzyme inhibition in essential hypertension. N Engl J Med 1979;301:9-15.
7. 7. Reams GP, Bauer JH, Gaddy P: Use of the converting enzyme inhibitor enalapril in renovascular hypertension. Effects on blood pressure, renal function and the renin-angiotensin-aldosterone system. Hypertension 1986;8:290-297.
8. 8. Kamper A-L, Thomsen HS, Nielsen SL, Strandgaard S: Initial effect of enalapril on kidney function in patients with moderate to severe chronic nephropathy. Scand J Urol Nephrol 1990;24:69-73.
9. 9. Björck S, Mulec H, Johnsen SA, et al: Renal protective effects of enalapril in diabetic nephropathy. Br Med J 1992;304:339-343.
10. 10. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
11. 51Cr-EDTA clearance as a measure of glomerular filtration rate. Scand J Clin Lab Invest 1981;41:611-616.
12. 12. Lindemann RD, Tobin JD, Schock NW: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984;26:861-868.
13. 13. Scaglione R, Ganguzza A, Corrao S, et al: Effects of cilazapril on renal haemodynamics and function in hypertensive patients: a randomized controlled study versus hydrochlorothiazide. Blood Pressure 1995;4: 363-368.